Press Releases Philogen S.p.A.

Equities

PHIL

IT0005373789

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-06-05 am EDT			5-day change	1st Jan Change
21.1 ^EUR	0.00%		+0.48%	+14.05%

Jun. 05	Mib bullish ahead of ECB; STM and Nexi soar	AN
Jun. 05	Mib rises; ECB could push cyclical stocks up	AN

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Philogen S p A : to attend the Chemical Biology conference at Novo Nordisk on June 8-9, 2024.	May. 23	PU
Philogen S p A : to attend the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 12, 2024.	Apr. 24	PU
Philogen S p A : is delighted to invite you to attend a virtual briefing on April 3, 2024 to discuss the Company’s Full Year 2023 Results.	Apr. 05	PU
Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma	Feb. 20	GL
Philogen S p A : to attend the Italian Mid Cap Conference organised by Mediobanca on January 23-24, 2024	Dec. 20	PU
Philogen S p A : to attend the Immunotherapy of Cancer Conference (ITOC) in Munich on March 21-23, 2024.	Dec. 20	PU
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities	Dec. 05	GL
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities	Dec. 05	AQ
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors	Dec. 04	GL
Philogen S p A : Ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	Nov. 05	PU
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma	23-10-16	GL
Philogen S p A : Settembre 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	23-10-04	PU
Philogen S p A : Agosto 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	23-09-05	PU
Philogen S p A : kindly invites you to attend a virtual briefing for analysts on 2 October 2023 to discuss Company’s Half Year 2023 Results	23-09-04	PU
Philogen S p A : Luglio 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	23-08-01	PU
Philogen S p A : announces new publication in Nature Chemistry	23-07-05	PU
Philogen S p A : Giugno 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	23-07-03	PU
Philogen S p A : Maggio 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	23-06-09	PU
Philogen S p A : kindly invites you to attend a virtual briefing for analysts on 5 June 2023 to discuss the Company’s latest updates.	23-06-04	PU
Philogen Announces Clinical Trial Collaboration with MSD	23-06-01	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Philogen S.p.A.

Equities

PHIL

IT0005373789

Press Releases

Filters